索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]沈迎,张瑞岩,沈卫峰.稳定性冠状动脉粥样硬化心脏病血运重建策略研究进展[J].国际心血管病杂志,2016,06:321-325.
点击复制

稳定性冠状动脉粥样硬化心脏病血运重建策略研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年06期
页码:
321-325
栏目:
综述
出版日期:
2016-11-20

文章信息/Info

Title:
-
作者:
沈迎; 张瑞岩; 沈卫峰
200025 上海交通大学医学院附属瑞金医院心内科
Author(s):
-
关键词:
稳定性冠状动脉粥样硬化心脏病; 经皮冠状动脉介入治疗; 冠状动脉旁路移植术; 功能学评估; 药物治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.06.001
文献标识码:
-
摘要:
稳定性冠状动脉(冠脉)粥样硬化心脏病(冠心病)极其常见,但对如何优化这类患者的处理策略(包括内科药物治疗和冠脉血运重建)尚存在争议。对某一患者而言,最佳的治疗方式需根据其具体冠脉病变程度和临床合并症情况决定。该文介绍新近关于稳定性冠心病血运重建策略以及冠脉病变功能学评估对血运重建的作用等研究进展。
Abstract:
-

参考文献/References

[1] Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J]. Circulation,2012,126(5):e354-e471.
[2] Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The task force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J, 2013,34(38):2949-3003.
[3] Qaseem A, Fihn SD, Williams S, et al. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons[J]. Ann Intern Med, 2012,157(10):729-734.
[4] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J]. Eur Heart J, 2014, 35(37): 2541-2619.
[5] 中华医学会心血管病分会介入心脏病学组,中国医师协会心血管内科医师分会,血栓防治专业委员会和中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志, 2016, 44(5): 382-400.
[6] Holmes DR, Taggart DP. Revascularization in stable coronary artery disease: a combined perspective from an interventional cardiologist and a cardiac surgeon[J]. Eur Heart J, 2016, 37(24): 1873-1882.
[7] Piccolo R, Ginstino G, Mehran R, et al. Stable coronary artery disease: revascularization and invasive strategies[J]. Lancet, 2015, 386(9994): 702-713.
[8] Iqbal J, Serruys PW. Revascularization strategies for patients with stable coronary artery diseas[J]. J Intern Med, 2014, 276(4): 336-351.
[9] Shaw LJ, Berman DS, Picard MH, et al. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging[J]. JACC Cardiovasc Imaging, 2014,7(6):593-604.
[10] De Bruyne B, Fearon WF, Pijls NH, et al. Fractional flow reserve -guided PCI for stable coronary artery disease[J]. N Engl J Med, 2014, 371(13): 1208-1217.
[11] Pijls NH, van Schaardenburgh P, Mannharn G, et al. Percutaneous coronary intervention of functionally unsignificant stenosis: 5-year follow-up of the DEFER Study[J]. J Am Coll Cardiol, 2007,49(21): 2105-2111.
[12] Sen S, Asrress KN, Nijjer S, et al. Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY(Classification Accuracy of Pressure Only Ratios Against Indices Using Flow Study)[J]. J Am Coll Cardiol, 2013, 61(13): 1409-1420.
[13] Mintz GS. Clinical utility of ultrasound imaging and physiology in coronary artery disease[J]. J Am Coll Cardiol, 2014, 64(2): 207-222.
[14] Belkacemi A, Stella PR, Ali DS, et al. Diagnostic accuracy of optical coherence tomography parameters in predicting in-stent hemodynamic severe coronary lesuions: validation against fractional flow reserve[J]. Int J Cardiol, 2013,168(4): 4209-4213.
[15] Windecker S, Stortecky S, Stefanini GG, et al. Revascularization versus medical treatment in patients with stable coronary artery disease: Network meta-analysis[J]. BMJ, 2014, 348:g3859.
[16] Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stants or bypass surgery for multivessel coronary disease[J]. N Engl J Med, 2015, 372(13): 1204-1212.
[17] Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease[J]. N Engl J Med, 2015, 372(13): 1213-1222.
[18] van Nunen LX, Zimmermann FM, Tonio PA, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease(FAME): 5-year follow-up of a randomized controlled trial[J]. Lancet, 2015, 386(10006):1853-1860.
[19] Athappan G, Patvardhan E, Tuzcu ME, et al. Left main coronary artery stenosis: a meta-analysis of drug-eluting stents versus coronary artery bypass grafting[J]. JACC Cardiovasc Interv, 2013,6(12): 1219-1230.
[20] Ahn JM, Roh JH, Kim YH, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. 5-year outcomes of the PRECOMBAT study[J]. J Am Coll Cardiol, 2015, 65(20): 2198-2206.
[21] Morice MC, Serruys PW, Kappetein AP, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial[J]. Circulation,2014, 129(23): 2388-2394.
[22] Verma S, Farkouh ME, Yanagawa B, et al. Comparison of coronary artery bypass grafting and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomized controlled trials[J]. Lancet Diabetes Endocrinol, 2013, 1(4): 317-328.
[23] Martinez SC, Holmes DR. Controversies surrounding percutaneous coronary intervention in the diabetic patient[J]. Expert Rev Cardiovasc Ther, 2016, 14(5): 633-648.
[24] Gansevoorti RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention[J]. Lancet, 2013, 382(9889): 339-352.
[25] Bax JJ, Delgado V, Bapat V, et al. Open issues in transcatheter aortic valve implantation. Part I: patient selection and treatment strategy for transcatheter aortic valve implantation[J]. Eur Heart J, 2014, 35(38): 2627-2638.
[26] Smith PK, Puskas JD, Ascheim DD. Surgical treatment of moderate mitral regurgitation[J]. N Engl J Med, 2014, 371(23): 2178-2188.
[27] Head SJ, Kaul S, Mack MJ, et al. The relation for Heart Team decision-making for patients with stable complex coronary artery disease[J]. Eur Heart J, 2013, 34(32): 2510-2518.
[28] Panoulas VF, Colomb A, Margonato A. Hybrid coronary revascularization: promising, but yet to take off[J]. J Am Coll Cardiol, 2015, 65(1): 85-97.
[29] Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischemic heart disease caused by de-novo native coronary artery lesions(ABSORB Ⅱ): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomized controlled trial[J]. Lancet, 2015, 385(9962): 43-54.
[30] Hande M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold(DREAM)in patients with de-novo coronary lesions: 12-month results of the prospective multicentre, first-in-man BIOSOLVE-1 trial[J]. Lancet, 2013, 381(9869): 836-844.
[31] Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary bypass grafting surgery: a scientific statement from the American Heart Association[J]. Circulation, 2015, 131(10): 927-964.
[32] Piccolo R, Windecker S. Dual antiplatelet therapy in percutaneous coronary intervention: A tale of 2 decades with new perspectives in the era of new-generation drug-eluting stents[J]. Circ Cardiovasc Interv, 2016, 9(2): e003587.
[33] Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2016, 68(10): 1116-1139.
[34] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of Cardiology/American Heart association task force on clinical practice guidelines[J]. Circulation, 2016, 134(10): e123-e155.
[35] Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual antiplatelet therpy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis[J]. J Am Coll Cardiol, 2015, 65(11): 1092-1102.
[36] Spencer FA, Prasad M, Vandvik PO, et al. Longer- versus shorter-duration dual antiplatelet therapy after drug-eluting stent placement: a systemic review and meta-analysis[J]. Ann Intern Med, 2015, 163(2): 118-126.
[37] Elmariah S, Mauri L, Doros G, et al. Extended duration of dual antiplatelet therapy and mortality: a systemic review and meta-analysis[J]. Lancet, 2015, 385(9970): 792-798.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2016-11-20